Anteris Technologies Global Corp. — Board/Management Information 2014

Oct 9, 2014

==> picture [226 x 82] intentionally omitted <==

ADMEDUS Ltd ABN 35 088 221 078

REGISTERED OFFICE: Level 1, 197 Adelaide Terrace Perth Western Australia 6000

PO Box 6879 East Perth Western Australia 6892

ASX ANNOUNCEMENT

T +61 (0)8 9266 0100 F +61 (0)8 9266 0199 E info.au@admedus.com

www.admedus.com

ADMEDUS APPOINTS TWO NEW BOARD DIRECTORS

• Mr. John Seaberg and Mr. Wayne Paterson will join the Board

• Both appointments add considerable experience from the pharmaceutical and medical device sectors

Brisbane, Australia, 10 October, 2014

Admedus Limited (ASX: AHZ) announced today that it has appointed two new Directors to its Board.

Mr. John Seaberg and Mr. Wayne Paterson have been appointed as independent, nonexecutive Directors.

“We welcome John Seaberg and Wayne Paterson to the Board and look forward to their insight and experience as Admedus continues to grow,” said Mr. Christopher Catlow, Chairman of Admedus.

Mr. Seaberg brings with him 37 years’ experience in the international medical devices industry with a strong background in development, sales and marketing. He has been involved in both national and multi-national medical device companies, particularly in the cardiovascular space.

Mr. Paterson joins Admedus after 20 years as a senior executive in the international pharmaceutical industry, with extensive managerial and marketing experience to the emerging, European and US markets.

“As Admedus grows its multi-national presence with the launch of CardioCel[®] , the experience and expertise of Mr. Seaberg and Mr. Paterson certainly strengthens the Board of Admedus,” added Mr. Catlow.

JOHN SEABERG

From 2007 until May 2014, Mr. Seaberg was Founder, Chairman and CEO of NeoChord Inc, a venture capital-backed company commercialising technology developed at the Mayo Clinic for the repair of the mitral valve via minimally invasive techniques.

Previously, he was employed by Guidant Corp from 1996 until 2006. Guidant was subsequently acquired by Boston Scientific Corp. During his ten years at Guidant, he served in various executive level positions in sales and marketing, including Director of Bradycardia Marketing for Cardiac Rhythm Management (CRM) and Vice President of Sales for Cardiac Surgery, in which he managed a field sales team of more than 600 people and over $1 billion in revenue.

Perth • Brisbane • Melbourne • Minneapolis • Zurich

==> picture [170 x 63] intentionally omitted <==

In 1991, Mr. Seaberg was a co-founder of ACIST Medical and served as its first President and CEO. ACIST manufactures and distributes power injection technologies for coronary angiography and was acquired by Bracco Ltd for $105 million in 2001. He was also the founder and CEO of Seaberg Medical, a regional distributor of implantable cardiovascular devices.

Mr. Seaberg served on the board of publicly traded Synovis Life Technologies (SYNO) from 2008 until its sale to Baxter Inc in 2012. At various times, he served as Chairman of the nominating and governance committee, member of the audit committee and Chairman of the Board. SYNO processed bovine tissue for use in various surgical applications.

Currently, Mr. Seaberg manages the healthcare consulting practice at Platinum Group and enjoys co-teaching a class at the Carlson School of Business (University of Minnesota) in entrepreneurial studies. Mr. Seaberg lives in the US.

Mr. Seaberg holds a Bachelor of Arts in Speech Communications from the University of Minnesota and a Masters in Business Administration (MBA) from the Carlson School of Management, also at the University of Minnesota.

WAYNE PATERSON

Mr. Paterson has held numerous, senior positions in multi-national companies. Throughout his career, he has been responsible for building businesses throughout the world, as well as mergers and major restructures.

From 2007 to 2013, Mr. Paterson held senior positions at Merck Serono. In his most recent position as President of Europe, Canada and Australia, he managed over $3 billion in sales with an operational budget of $500 million. Mr. Paterson also held the position of Global Head of Cardio Metabolic Care and General Medicine, with revenue responsibility of $1.5 billion, and was responsible for all aspects of company strategy, including manufacturing strategies, commercial operations and budgets.

Between 2010 and 2012, Mr. Paterson was Head of Emerging Markets including Russia, China, India and Brazil, and was a member of the Executive Board. As President during 2007 until 2010 in Japan, Mr. Paterson created Merck Serono Japan and successfully managed all company divisions, launching several major products. In this capacity, Mr. Paterson served as Chairman of the Board of Merck Serono Japan.

Between 1994 and 2005, Mr.Paterson was employed by Roche Pharmaceuticals. As Marketing Director in Shanghai, China, he launched eight products during this time, including cardiovascular products.

Mr. Paterson is an Australian national and has resided overseas since 1999, having lived in China, Singapore, Korea, Japan, Switzerland and the US. He now lives in Switzerland, where he is CEO and co-founder of a software company that provides solutions to the global pharmaceutical industry.

Mr. Paterson holds a MBA from the University of Southern Queensland, and a degree in business studies from the Queensland University of Technology. He has also studied business courses at North Western University (Kellog School of Management) in Chicago, IMD Business School in Switzerland, INSEAD in France and Hong Kong University of Technology.

Perth • Brisbane • Melbourne • Minneapolis • Zurich

==> picture [170 x 63] intentionally omitted <==

For more information, please contact:

Dr Julian Chick | Chief Operating Officer | Admedus Limited Tel: +61 3 9620 5454

Media :

Hayley Price +61 (0) 423 139 163 hprice@admedus.com

About Admedus Limited

Admedus (ASX: AHZ) is a diversified healthcare company focused on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow its product and service offerings and expanding revenues from its existing profitable medical sales and distribution business. The Company has assets from research & development through clinical development as well as sales, marketing and distribution.

Admedus is in the process of commercialising its innovative tissue engineering technology for regenerative medicine. Admedus also has a major interest in developing the next generation of vaccines with a Brisbane-based research group, lead by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.

Further information on the company can be found at www.admedus.com

Perth • Brisbane • Melbourne • Minneapolis • Zurich